Cancer Treatment Reviews
Volume 31 , Pages S23-S28 , 2005

What is the best schedule for administration of gemcitabine-taxane?

References 

  1. O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol. 2002;20(12):2812–2823
  2. (July 15 Suppl) Albain KS, Nag S, Calderillo-Ruiz G, et al. Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): first report of overall survival. J Clin Oncol 2004; ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2004;22(14S):510
  3. Fornier M, Norton L. Dose-dense adjuvant chemotherapy for primary breast cancer. Breast Cancer Res. 2005;7(2):64–69
  4. Del Mastro L, Venturini M, Lionetto R, et al. Accelerated-intensified cyclophosphamide, epirubicin, and fluorouracil (CEF) compared with standard CEF in metastatic breast cancer patients: results of a multicentre, randomized phase III study of the Italian Gruppo Oncologico Nord-Ouest-Mammella Inter Gruppo Group. J Clin Oncol. 2001;19(8):2213–2221
  5. Baldini E, Gardin G, Giannessi PG, et al. Accelerated versus standard cyclophosphamide, epirubicin and 5-fluorouracil or cyclophosphamide, methotrexate and 5-fluorouracil: a randomized phase III trial in locally advanced breast cancer. Ann Oncol. 2003;14:227–232
  6. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of intergroup trial C9741/Cancer and Leukaemia Group B Trial 9741. J Clin Oncol. 2003;21:1431–1439
  7. Vermorken JB, Guastalla JP, Hatty SR, et al. Phase I study of gemcitabine using a once every 2 weeks schedule. Br J Cancer. 1997;76(11):1489–1493
  8. Rothenburg ML, Sharma A, Weiss GR, et al. Phase I trial of paclitaxel and gemcitabine administered every 2 weeks in patients with refractory solid tumors. Ann Oncol. 1998;9(7):733–738
  9. James R, Rothenburg ML, Davis TH. Phase I clinical and pharmacokinetic study of docetaxel in combination with two gemcitabine combination schedules. 1999 ASCO Annual Meeting. Abstract 870.
  10. Castellano D, Hitt R, Ciruelos E, et al. Biweekly vinorelbine and gemcitabine: a phase I dose-finding study in patients with advanced solid tumors. Ann Oncol. 2003;14:783–787
  11. Colomer R, Llambart-Cussac , Lluch A, et al. Biweekly paclitaxel plus gemcitabine in advanced breast cancer: phase II trial and predictive value of HER2 extracellular domain. Ann Oncol. 2004;15(2):201–206
  12. Alexopoulos A, Tryfonopoulos D, Karamouzis MV, et al. Evidence for in vivo synergism between docetaxel and gemcitabine in patients with metastatic breast cancer. Ann Oncol. 2004;15(1):95–99
  13. Abstract 5061 Oliveras C, Vázquez-Martín A, Ferrer L, et al. Gemcitabine plus paclitaxel, is there a better Schedule for treatment?. Breast Cancer Res and Treat. 2004;88(Suppl 1):
  14. Abstract Pelegri A, Calvo L, Mayordomo JI, et al. Gemcitabine and docetaxel given every 2 weeks as first-line therapy for metastatic breast cancer (MBC): results of a GEICAM phase II study. In: 2002 ASCO Annual Meeting. 1950;
  15. Mavroudis D, Malamos N, Polyzos A, et al. Front-Line Chemotherapy with docetaxel plus gemcitabine administratered every two weeks in patients with metastatic breast cancer: A multicenter phase II study. Oncology. 2004;67:250–256
  16. Kornek G, Haider K, Kwasny W, et al. Treatment of Advanced Breast Cancer with Docetaxel and Gemcitabine with and without Human Granulocyte Colony-stimulating Factor. Clinical Cancer Research. 2002;8:1051–1056
  17. Sánchez-Rovira P, Carrasco E, Jaén A, et al. Activity and tolerability of bi-weekly paclitaxel and gemcitabine every 4 weeks in previously treated patients with metastatic breast cancer. Am J Clin Oncol., in press.
  18. Abstract 2054 Vici P, Fogg P, Capomolla E, et al. Biweekly paclitaxel/gemcitabine (P/G) as salvage treatment in breast cancer patients (pts): preliminary results. In: ASCO Annual Meeting. 2002;
  19. Colomer R, Llombart-Cussac A, Tusquets I, Rifà J, Mayordomo JI, Ojeda B, Castellano D, Valentín V, Hornedo J, Cortés-Funes H. Biweekly gemcitabine plus vinorelbine in first-line metastatic breast cancer: Efficacy and predictive value of HER2 extracellular domain (ECD). Manuscript submitted.
  20. Stathopoulos GP, Rigatos SK, Pergantas N, et al. Phase II trial of biweekly administration of vinorelbine and gemcitabine in pretreated advanced breast cancer. J Clin Oncol. 2002;20(1):37–41
  21. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–792
  22. Rahman ZU, Frye DK, Smith TL, et al. Results and long-term follow up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy. A reference. Cancer. 1999;85(1):104–111

PII: S0305-7372(05)80005-2

Cancer Treatment Reviews
Volume 31 , Pages S23-S28 , 2005

Article Tools